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ABSTRACT 
Amyloid-related imaging abnormalities (ARIA), thought to reflect immune responses 
to vascular amyloid, have been detected in several amyloid-modifying therapy trials 
for Alzheimer’s disease (AD). We report a case of ARIA developing spontaneously 
during the course of Presenilin 1 (PSEN1)-associated familial AD (FAD), in an 
APOE4 homozygous patient. Severe cerebral amyloid angiopathy (CAA) with 
associated inflammation was subsequently found at autopsy. Recognition that ARIA 
may arise spontaneously during FAD and of the potential risk factors for its 
development are important observations given the recent launch of amyloid-
modifying therapy trials for FAD. 
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INTRODUCTION 
The term ‘ARIA’ has been proposed to describe the amyloid-related MRI 
abnormalities observed in a number of patients participating in various amyloid-
modifying therapy trials for AD [1-5]. ARIA refers to a spectrum of imaging changes 
and may be subdivided into ARIA-E, describing increased signal on fluid-attenuated 
inversion recovery (FLAIR) and other T2-weighted MRI sequences, thought to 
represent cerebral oedema and effusion or extravasated fluid in sulcal spaces, and 
ARIA-H, denoting microhaemorrhages and superficial siderosis evident on gradient 
echo (T2*-GRE) sequences. ARIA are thought to reflect changes involving vascular 
amyloid, although a detailed understanding of their pathogenesis remains to be 
elucidated. Recognition that the clinical and neuroimaging features of ARIA are 
similar, although in general milder, to those of the spontaneously occurring condition 
CAA-related inflammation (CAA-ri) supports the hypothesis that an immunological 
response to vascular amyloid, with increased vascular permeability, may be a 
common underlying pathophysiological mechanism [6]. Some degree of CAA is 
found at post-mortem in up to 90% of AD patients [7] and the observation of changes 
resembling ARIA-E in a small number of cases undergoing screening for clinical 
trials suggests that it may rarely occur during the natural history of AD [8]. Its 
prevalence, however, is unknown and to our knowledge this is the first reported case 
of ARIA-E developing spontaneously during the course of PSEN1-associated FAD.  
 
CASE REPORT 
The patient developed gradual impairment of episodic memory from age 48. She 
was an ex-smoker with a history of treated hypercholesterolaemia and depression. 
On initial assessment, aged 53, she had finger myoclonus bilaterally and scored 
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25/30 on the MMSE. Neuropsychological assessment revealed significant 
impairment of immediate and delayed recall memory with language function at the 
lower limit of normal. Visuospatial and executive functions were relatively intact. A 
lumbar puncture (LP) demonstrated acellular CSF with a protein level of 0.4g/L. As a 
similar illness had affected her father from the age of 67 and two of her sisters from 
their early 50s, genetic testing was carried out. This identified the novel PSEN1 
I202F mutation in the patient and her affected siblings [9]. Her APOE genotype was 
e4 homozygous. She was treated with a cholinesterase inhibitor and the first nine 
years of her illness followed a gradually progressive course. At the age of 57, she 
underwent a sub-acute deterioration in cognition and behaviour over a period of 
several weeks, becoming more emotionally labile and losing the ability to dress 
herself or hold a conversation. There were no associated headaches, seizures or 
signs of systemic infection. An MRI scan at this stage demonstrated florid white 
matter hyperintensities, particularly in a parieto-occipital distribution where they 
extended to involve the U-fibres and were associated with marked focal loss of sulcal 
spaces suggestive of oedema (Figure 1). The imaging abnormalities were bilateral 
but more prominent in the left hemisphere. T2*-GRE sequences were not acquired. 
The prospect of a further LP and steroid treatment was discussed with her family but 
a conservative approach was chosen. Her agitation improved on Quetiapine and the 
course of her cognitive impairment appeared to return to the gradual rate of decline 
which it had previously followed. A follow up MRI nine months later showed that 
there had been some spontaneous improvement in the severity of white matter 
change and oedema. Unfortunately, she was unable to tolerate scanning long 
enough to acquire T2-FLAIR and T2*-GRE sequences on this occasion. Two months 
after the final scan she developed visual hallucinations and misperceptions, motor 
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stereotypies and worsened agitation. An empirical trial of Prednisolone was given for 
a month; the family felt that this was associated with some functional improvement 
initially but it was not sustained and she couldn’t tolerate increased doses. She 
continued to deteriorate, developed seizures and was admitted to a Nursing Home. 
She died 10 months after her final scan and 11 years after the onset of her illness.  
 
Her brain was donated to the Queen Square Brain Bank for Neurological Disorders 
where tissue is stored under a licence from the Human Tissue Authority. Brain 
weight was 1038g and macroscopic investigation confirmed severe cerebral atrophy, 
reduction in bulk of the hemispheric white matter, marked reduction in size of the 
hippocampus and amygdala and pallor of the locus coeruleus. Microscopic 
investigation of histological slides from representative regions of the right 
hemisphere of the brain demonstrated end-stage AD pathology with severe 
neurofibrillary tangle pathology (Braak and Braak stage VI) and extensive mature 
and diffuse Aβ-positive parenchymal plaques (Thal phase 5). Tau 
immunohistochemistry confirmed the presence of ‘frequent’ neuritic plaques in all 
CERAD (Consortium to Establish a Registry for AD) cortical regions.  Aβ 
immunohistochemistry also revealed ‘severe’ CAA with focal collections of 
mononuclear inflammatory cells, mostly CD3-positive T lymphocytes and CD68-
positive macrophages, around some of the leptomeningeal and cortical blood 
vessels. One leptomeningeal small arteriole showed invasion of its thickened walls 
by CD3-positive T-cells (Figure 2), but no multinucleated giant cells were identified. 
Using special stain (MSB method) no fibrinoid necrosis of the walls of this or other 
leptomeningeal or cortical blood vessels could be demonstrated. A sparse diffuse 
chronic inflammatory cell infiltrate was present in the leptomeninges. In addition, 
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there was marked diffuse increase of CD68-positive microglia/macrophages in the 
parenchyma of both cerebral cortex and subcortical white matter, which was slightly 
more severe in the temporal, parietal and occipital areas than in the frontal region. 
No haemorrhagic changes were seen. Some of the macrophages were observed to 
contain pigment, however this was negative for haemosiderin on Perls stain. As the 
MRI changes were more prominent in the left hemisphere, frozen tissue from the left 
parietal and occipital cortices was also examined. This demonstrated a small, 
cavitating infarct in the left occipital cortex and subcortical white matter invaded by 
macrophages and T lymphocytes. Macrophages and microglia were focally 
numerous in the surrounding brain parenchyma surrounding the infarct. -Synuclein 
immunohistochemistry demonstrated amygdala predominant Lewy pathology.  
 
DISCUSSION 
The appearance of ARIA-E in this patient coincided with a period of clinical 
deterioration. As there was an interval of almost two years between this episode and 
the post-mortem examination, the exact cause of the imaging abnormalities can only 
be hypothesised. However, the pathological findings do support the idea that an 
immune/inflammatory response to vascular amyloid was implicated. There was 
severe CAA, with a chronic inflammatory infiltrate surrounding some of the cortical 
and leptomeningeal blood vessels. One leptomeningeal arteriole also showed 
transmural inflammation indicative of vasculitis. This case therefore adds further 
support to a growing body of literature linking CAA-ri to radiological features 
described as ARIA [10]. Whilst the precise underlying pathogenetic mechanisms are 
not yet fully understood, previous observations of CD68+ macrophages and CD4+ T-
cell recruitment at sites of Aβ-related angiitis [11, 12] and CSF anti-Aβ 
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autoantibodies in patients with spontaneous CAA-ri [6, 13] support the notion of an 
autoimmune response against vascular Aβ [10]. 
 
Several factors may have predisposed the patient to developing this complication. 
PSEN1 mutations located beyond codon 200 have been reported to be associated 
with particularly severe CAA [14], and her APOE-e4 homozygosity may have 
increased her risk of developing CAA-ri. In clinical trials of the humanized anti-Aβ 
antibody bapineuzumab, the frequency of ARIA-E increased with APOE-e4 gene 
dose [4, 5]. Spontaneous CAA-ri is also associated with APOE-e4 homozygosity [15, 
16]. Capillary CAA, observed in the occipital cortex of this patient, may play an 
important role here as it has been found to both associate with the APOE-e4 allele 
[17] and to provoke a particularly strong inflammatory response, unlike larger vessel 
CAA [18]. This individual’s vascular risk factors may have rendered her further 
vulnerable to developing blood-brain barrier dysfunction and increased vascular 
permeability. Investigation of the degree of CAA and inflammation in APOE-e4 non-
carriers with this PSEN1 mutation would be an interesting avenue for future 
research. 
 
The development of ARIA-E should be further evaluated as a possible cause of sub-
acute deterioration in patients with established AD. Recognition that it may arise 
spontaneously during the course of FAD is particularly timely with amyloid-modifying 
therapy trials for FAD underway. Although many of the participants in these trials will 
be presymptomatic, certain genetic factors may increase the risk of developing 
ARIA, even prior to the onset of clinical disease. This has been illustrated by a case 
report of ARIA developing spontaneously in a cognitively normal APP duplication 
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carrier [19]. Monitoring for ARIA, investigating the underlying pathophysiological 
mechanisms and identifying individuals at increased risk of developing them will be a 
crucial part of both natural history studies and treatment trials in AD. 
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Figure 1. Serial MRI scans demonstrating the appearance and then subsequent 
partial resolution of ARIA  
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Figure 2. Pathological analysis.  
Macroscopic observation of coronal slices confirmed cerebral atrophy and dilatation 
of the lateral ventricle with a reduction in bulk of the deep white matter and size of 
the hippocampus (A; arrow). Aβ immunohistochemistry showed numerous plaques 
(B) both cored (C) and diffuse. Severe CAA was found in the parenchyma (B, arrow) 
and leptomeninges (D) and was also found to affect capillaries in the occipital cortex 
(E). Numerous neurofibrillary tangles and neuropil threads were highlighted with tau 
immunohistochemistry (F) in the CA1 hippocampal subregion. Severe gliosis was 
observed throughout all cortical regions with GFAP immunohistochemistry (G) 
together with increased numbers of reactive microglia (H). Additional Lewy body and 
Lewy neurite pathology was seen in the amygdala (I). Some leptomeningeal blood 
vessels were surrounded by focal collections of mononuclear inflammatory cells, 
mostly CD3-positive T lymphocytes and CD68-positive macrophages (K), with one 
leptomeningeal small arteriole showing invasion of its thickened walls by CD3-
positive T-cells (L). B-I and K and L are immunohistochemical preparations, B-E: 
A ; F: Tau (AT8 antibody); G: GFAP; H and K: CD68; I: -Synuclein; L: 
CD3; J: Haematoxylin and eosin. Bar in B represents 100μm in B, D; 50 μm in H, J, 
K and L; 20μm in C,E, F and I.  
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